Contrast Induced Nephropathy News and Research

RSS
Contrast-induced nephropathy (CIN) is a common complication of radiographic procedures and is the third leading cause of hospital aquired renal failure. It is associated with significant morbidity and mortality.
Beetroot may reduce kidney failure risk after heart x-ray, research reveals

Beetroot may reduce kidney failure risk after heart x-ray, research reveals

Intravenous contrast media used in CT not linked to increased risk of acute kidney injury

Intravenous contrast media used in CT not linked to increased risk of acute kidney injury

Simple diagnostic algorithm to assess pulmonary embolism risk can help reduce rate of CTPA imaging

Simple diagnostic algorithm to assess pulmonary embolism risk can help reduce rate of CTPA imaging

New iodine-based contrast material enhances CT images to safely use in most patients

New iodine-based contrast material enhances CT images to safely use in most patients

Complete revascularisation leads to better outcomes in patients with heart attack

Complete revascularisation leads to better outcomes in patients with heart attack

Dye reduction in diagnostic heart procedures: an interview with Mike McCormick, CEO Osprey Medical

Dye reduction in diagnostic heart procedures: an interview with Mike McCormick, CEO Osprey Medical

Preventive PCI for patients with ST elevation myocardial infarction results in better outcomes

Preventive PCI for patients with ST elevation myocardial infarction results in better outcomes

LVEDP-guided hydration effectively prevents CI-AKI in patients undergoing cardiac catheterization

LVEDP-guided hydration effectively prevents CI-AKI in patients undergoing cardiac catheterization

Osprey Medical closes IPO raising of A$20 million

Osprey Medical closes IPO raising of A$20 million

PLC Systems fourth quarter total revenues increase to $189,000

PLC Systems fourth quarter total revenues increase to $189,000

PLC receives Brazilian government approval to market RenalGuard System

PLC receives Brazilian government approval to market RenalGuard System

Exposure to iodinated contrast media may increase risk of hyperthyroidism

Exposure to iodinated contrast media may increase risk of hyperthyroidism

PLC Systems initiates enrollment in RenalGuard pivotal trial for CIN

PLC Systems initiates enrollment in RenalGuard pivotal trial for CIN

MYTHOS clinical trial demonstrates superiority of RenalGuard in reducing CIN

MYTHOS clinical trial demonstrates superiority of RenalGuard in reducing CIN

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

FDA approves PLC's U.S. pivotal trial of RenalGuard to prevent Contrast-Induced Nephropathy

PLC Systems second quarter total revenues increase to $398,000

PLC Systems second quarter total revenues increase to $398,000

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

PLC Systems to showcase RenalGuard at 2011 EAPCI annual meeting

PLC Systems to showcase RenalGuard at 2011 EAPCI annual meeting

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference

PLC's RenalGuard System REMEDIAL II trial final results to be presented at ACC conference